A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH PHASE 3 STUDY TO EVALUATE THE EFFECT OF VENGLUSTAT ON NEUROPATHIC AND ABDOMINAL PAIN IN MALE AND FEMALE PARTICIPANTS ¿16 YEARS OF AGE WITH FABRY DISEASE WHO ARE TREATMENT-NAÏVE OR UNTREATED FOR AT LEAST 6 MONTHS
- Registry ID
- EFC17045
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- SANOFI-AVENTIS CANADA INC
- Start date
- 2023-12-16
- Last update
- 2021-10-05
Conditions
Related clinical trials
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, 18-MONTH PHASE 3 STUDY TO EVALUATE THE EFFECT OF VENGLUSTAT COMPARED WITH USUAL STANDARD OF CARE ON LEFT VENTRICULAR MASS INDEX IN PARTICIPANTS WITH FABRY DISEASE AND LEFT VENTRICULAR HYPERTROPHY
- A PHASE I/II, MULTICENTER, OPEN-LABEL, SINGLE-DOSE, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ST-920, A AAV2/6 HUMAN ALPHA GALACTOSIDASE A GENE THERAPY IN SUBJECTS WITH FABRY DISEASE
- A MULTI-CENTER, OPEN-LABEL, UNCONTROLLED, SINGLE-ARM, EXTENSION STUDY TO DETERMINE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL LUCERASTAT IN ADULT SUBJECTS WITH FABRY DISEASE
- OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGUNIGALSIDASE ALFA (PRX-102) IN PATIENTS WITH FABRY DISEASE
- A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LUCERASTAT ORAL MONOTHERAPY IN ADULT SUBJECTS WITH FABRY DISEASE.
- A PHASE 3, OPEN LABEL, SWITCH OVER STUDY TO ASSESS THE SAFETY, EFFICACY AND PHARMACOKINETICS OF PEGUNIGALSIDASE ALFA (PRX-102) 2MG/KG ADMINISTERED BY INTRAVENOUS INFUSION EVERY 4 WEEKS FOR 52 WEEKS IN PATIENTS WITH FABRY DISEASE CURRENTLY TREATED WITH ENZYME REPLACEMENT THERAPY: FABRAZYME (AGALSIDASE BETA) OR REPLAGAL (AGALSIDASE ALFA)
View on source registry